APO Research
Talk to an analyst

APO RESEARCH · REPORT

Immuno-oncology Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Research

Immuno-oncology Drugs Industry Research Report 2026

22 December 2025141 pages

Choose your research edition.

Industry ResearchImmuno-oncology Drugs Industry Research Report 2026141 pages · $2,950 USDIndustry Growth & TrendsGlobal Immuno-oncology Drugs Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Immuno-oncology Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Immuno-oncology Drugs Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Immuno-oncology Drugs Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global Immuno-oncology Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the Immuno-oncology Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Immuno-oncology Drugs market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Immuno-oncology Drugs market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Immuno-oncology Drugs include Sanofi S.A., Johnson & Johnson, Merck & Co., Lonza Group, Eli Lilly and Company, Pfizer Inc., Ferring Pharmaceuticals, Amgen, Inc and AbbVie, Inc., among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

Read the full market overview

This report quantifies the global Immuno-oncology Drugs market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Immuno-oncology Drugs.

Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Immuno-oncology Drugs Market by Company

Sanofi S.A.

Johnson & Johnson

Merck & Co.

Lonza Group

Eli Lilly and Company

Pfizer Inc.

Ferring Pharmaceuticals

Amgen, Inc

AbbVie, Inc.

AstraZeneca, Plc

Spring Bank Pharmaceuticals, Inc.

Prometheus Therapeutics & Diagnostics

Novartis International AG

Incyte

ImmunoCellular Therapeutics

Hoffmann-La Roche AG

Gilead Sciences Inc.

Galena Biopharma

Enzo Biochem, Inc.

EMD Serono, Inc.

Dendreon Corporation

Celldex Therapeutics

Celgene Corporation

Bristol-Myers Squibb

Bio-Rad Laboratories, Inc.

Bavarian Nordic

Avantor, Inc.

Agilent Technologies Inc.

Agenus Inc.

Aduro BioTech

Immuno-oncology Drugs Segment by Type

Oncolytic Virus

Immune System Modulators

Immune Checkpoint Inhibitors

Cancer Vaccines

Others

Immuno-oncology Drugs Segment by Application

Clinics

Hospitals

Community Centers

Immuno-oncology Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Russia

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Saudi Arabia

Israel

United Arab Emirates

Turkey

Iran

Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Immuno-oncology Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Immuno-oncology Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Immuno-oncology Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Immuno-oncology Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Immuno-oncology Drugs Market Size by Type (2021-2026) & (US$ Million) Table 6. Global Immuno-oncology Drugs Revenue Market Share by Type (2021-2026) Table 7. Global Immuno-oncology Drugs Forecasted Market Size by Type (2027-2032) & (US$ Million) Table 8. Global Immuno-oncology Drugs Revenue Market Share by Type (2027-2032) Table 9. Global Immuno-oncology Drugs Market Size by Application (2021-2026) & (US$ Million) Table 10. Global Immuno-oncology Drugs Revenue Market Share by Application (2021-2026) Table 11. Global Immuno-oncology Drugs Forecasted Market Size by Application (2027-2032) & (US$ Million) Table 12. Global Immuno-oncology Drugs Revenue Market Share by Application (2027-2032) Table 13. Global Immuno-oncology Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Immuno-oncology Drugs Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Immuno-oncology Drugs Market Share by Region (2021-2026) Table 16. Global Immuno-oncology Drugs Forecasted Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Immuno-oncology Drugs Market Share by Region (2027-2032) Table 18. Immuno-oncology Drugs Industry Trends Table 19. Immuno-oncology Drugs Industry Drivers Table 20. Immuno-oncology Drugs Industry Opportunities and Challenges Table 21. Immuno-oncology Drugs Market Restraints Table 22. Global Top Immuno-oncology Drugs Players by Revenue (US$ Million) & (2021-2026) Table 23. Global Immuno-oncology Drugs Revenue Market Share by Players (2021-2026) Table 24. Global Immuno-oncology Drugs Industry Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Key Players of Immuno-oncology Drugs, Headquarters and Area Served Table 26. Global Immuno-oncology Drugs Players, Product Type & Application Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Immuno-oncology Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Players Mergers & Acquisitions, Expansion Plans Table 30. North America Immuno-oncology Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 31. North America Immuno-oncology Drugs Market Size by Country (2021-2026) & (US$ Million) Table 32. North America Immuno-oncology Drugs Market Size by Country (2027-2032) & (US$ Million) Table 33. Europe Immuno-oncology Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Europe Immuno-oncology Drugs Market Size by Country (2021-2026) & (US$ Million) Table 35. Europe Immuno-oncology Drugs Market Size by Country (2027-2032) & (US$ Million) Table 36. Asia Pacific Immuno-oncology Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Asia Pacific Immuno-oncology Drugs Market Size by Region (2021-2026) & (US$ Million) Table 38. Asia Pacific Immuno-oncology Drugs Market Size by Country (2027-2032) & (US$ Million) Table 39. South America Immuno-oncology Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. South America Immuno-oncology Drugs Market Size by Country (2021-2026) & (US$ Million) Table 41. South America Immuno-oncology Drugs Market Size by Country (2027-2032) & (US$ Million) Table 42. Middle East & Africa Immuno-oncology Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 43. Middle East & Africa Immuno-oncology Drugs Market Size by Country (2021-2026) & (US$ Million) Table 44. Middle East & Africa Immuno-oncology Drugs Market Size by Country (2027-2032) & (US$ Million) Table 45. Sanofi S.A. Company Information Table 46. Sanofi S.A. Business Overview Table 47. Sanofi S.A. Revenue in Immuno-oncology Drugs Business (2021-2026) & (US$ Million) Table 48. Sanofi S.A. Immuno-oncology Drugs Product Portfolio Table 49. Sanofi S.A. Recent Developments Table 50. Johnson & Johnson Company Information Table 51. Johnson & Johnson Business Overview Table 52. Johnson & Johnson Revenue in Immuno-oncology Drugs Business (2021-2026) & (US$ Million) Table 53. Johnson & Johnson Immuno-oncology Drugs Product Portfolio Table 54. Johnson & Johnson Recent Developments Table 55. Merck & Co. Company Information Table 56. Merck & Co. Business Overview Table 57. Merck & Co. Revenue in Immuno-oncology Drugs Business (2021-2026) & (US$ Million) Table 58. Merck & Co. Immuno-oncology Drugs Product Portfolio Table 59. Merck & Co. Recent Developments Table 60. Lonza Group Company Information Table 61. Lonza Group Business Overview Table 62. Lonza Group Revenue in Immuno-oncology Drugs Business (2021-2026) & (US$ Million) Table 63. Lonza Group Immuno-oncology Drugs Product Portfolio Table 64. Lonza Group Recent Developments Table 65. Eli Lilly and Company Company Information Table 66. Eli Lilly and Company Business Overview Table 67. Eli Lilly and Company Revenue in Immuno-oncology Drugs Business (2021-2026) & (US$ Million) Table 68. Eli Lilly and Company Immuno-oncology Drugs Product Portfolio Table 69. Eli Lilly and Company Recent Developments Table 70. Pfizer Inc. Company Information Table 71. Pfizer Inc. Business Overview Table 72. Pfizer Inc. Revenue in Immuno-oncology Drugs Business (2021-2026) & (US$ Million) Table 73. Pfizer Inc. Immuno-oncology Drugs Product Portfolio Table 74. Pfizer Inc. Recent Developments Table 75. Ferring Pharmaceuticals Company Information Table 76. Ferring Pharmaceuticals Business Overview Table 77. Ferring Pharmaceuticals Revenue in Immuno-oncology Drugs Business (2021-2026) & (US$ Million) Table 78. Ferring Pharmaceuticals Immuno-oncology Drugs Product Portfolio Table 79. Ferring Pharmaceuticals Recent Developments Table 80. Amgen, Inc Company Information Table 81. Amgen, Inc Business Overview Table 82. Amgen, Inc Revenue in Immuno-oncology Drugs Business (2021-2026) & (US$ Million) Table 83. Amgen, Inc Immuno-oncology Drugs Product Portfolio Table 84. Amgen, Inc Recent Developments Table 85. AbbVie, Inc. Company Information Table 86. AbbVie, Inc. Business Overview Table 87. AbbVie, Inc. Revenue in Immuno-oncology Drugs Business (2021-2026) & (US$ Million) Table 88. AbbVie, Inc. Immuno-oncology Drugs Product Portfolio Table 89. AbbVie, Inc. Recent Developments Table 90. AstraZeneca, Plc Company Information Table 91. AstraZeneca, Plc Business Overview Table 92. AstraZeneca, Plc Revenue in Immuno-oncology Drugs Business (2021-2026) & (US$ Million) Table 93. AstraZeneca, Plc Immuno-oncology Drugs Product Portfolio Table 94. AstraZeneca, Plc Recent Developments Table 95. Spring Bank Pharmaceuticals, Inc. Company Information Table 96. Spring Bank Pharmaceuticals, Inc. Business Overview Table 97. Spring Bank Pharmaceuticals, Inc. Revenue in Immuno-oncology Drugs Business (2021-2026) & (US$ Million) Table 98. Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Product Portfolio Table 99. Spring Bank Pharmaceuticals, Inc. Recent Developments Table 100. Prometheus Therapeutics & Diagnostics Company Information Table 101. Prometheus Therapeutics & Diagnostics Business Overview Table 102. Prometheus Therapeutics & Diagnostics Revenue in Immuno-oncology Drugs Business (2021-2026) & (US$ Million) Table 103. Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Product Portfolio Table 104. Prometheus Therapeutics & Diagnostics Recent Developments Table 105. Novartis International AG Company Information Table 106. Novartis International AG Business Overview Table 107. Novartis International AG Revenue in Immuno-oncology Drugs Business (2021-2026) & (US$ Million) Table 108. Novartis International AG Immuno-oncology Drugs Product Portfolio Table 109. Novartis International AG Recent Developments Table 110. Incyte Company Information Table 111. Incyte Business Overview Table 112. Incyte Revenue in Immuno-oncology Drugs Business (2021-2026) & (US$ Million) Table 113. Incyte Immuno-oncology Drugs Product Portfolio Table 114. Incyte Recent Developments Table 115. ImmunoCellular Therapeutics Company Information Table 116. ImmunoCellular Therapeutics Business Overview Table 117. ImmunoCellular Therapeutics Revenue in Immuno-oncology Drugs Business (2021-2026) & (US$ Million) Table 118. ImmunoCellular Therapeutics Immuno-oncology Drugs Product Portfolio Table 119. ImmunoCellular Therapeutics Recent Developments Table 120. Hoffmann-La Roche AG Company Information Table 121. Hoffmann-La Roche AG Business Overview Table 122. Hoffmann-La Roche AG Revenue in Immuno-oncology Drugs Business (2021-2026) & (US$ Million) Table 123. Hoffmann-La Roche AG Immuno-oncology Drugs Product Portfolio Table 124. Hoffmann-La Roche AG Recent Developments Table 125. Gilead Sciences Inc. Company Information Table 126. Gilead Sciences Inc. Business Overview Table 127. Gilead Sciences Inc. Revenue in Immuno-oncology Drugs Business (2021-2026) & (US$ Million) Table 128. Gilead Sciences Inc. Immuno-oncology Drugs Product Portfolio Table 129. Gilead Sciences Inc. Recent Developments Table 130. Galena Biopharma Company Information Table 131. Galena Biopharma Business Overview Table 132. Galena Biopharma Revenue in Immuno-oncology Drugs Business (2021-2026) & (US$ Million) Table 133. Galena Biopharma Immuno-oncology Drugs Product Portfolio Table 134. Galena Biopharma Recent Developments Table 135. Enzo Biochem, Inc. Company Information Table 136. Enzo Biochem, Inc. Business Overview Table 137. Enzo Biochem, Inc. Revenue in Immuno-oncology Drugs Business (2021-2026) & (US$ Million) Table 138. Enzo Biochem, Inc. Immuno-oncology Drugs Product Portfolio Table 139. Enzo Biochem, Inc. Recent Developments Table 140. EMD Serono, Inc. Company Information Table 141. EMD Serono, Inc. Business Overview Table 142. EMD Serono, Inc. Revenue in Immuno-oncology Drugs Business (2021-2026) & (US$ Million) Table 143. EMD Serono, Inc. Immuno-oncology Drugs Product Portfolio Table 144. EMD Serono, Inc. Recent Developments Table 145. Dendreon Corporation Company Information Table 146. Dendreon Corporation Business Overview Table 147. Dendreon Corporation Revenue in Immuno-oncology Drugs Business (2021-2026) & (US$ Million) Table 148. Dendreon Corporation Immuno-oncology Drugs Product Portfolio Table 149. Dendreon Corporation Recent Developments Table 150. Celldex Therapeutics Company Information Table 151. Celldex Therapeutics Business Overview Table 152. Celldex Therapeutics Revenue in Immuno-oncology Drugs Business (2021-2026) & (US$ Million) Table 153. Celldex Therapeutics Immuno-oncology Drugs Product Portfolio Table 154. Celldex Therapeutics Recent Developments Table 155. Celgene Corporation Company Information Table 156. Celgene Corporation Business Overview Table 157. Celgene Corporation Revenue in Immuno-oncology Drugs Business (2021-2026) & (US$ Million) Table 158. Celgene Corporation Immuno-oncology Drugs Product Portfolio Table 159. Celgene Corporation Recent Developments Table 160. Bristol-Myers Squibb Company Information Table 161. Bristol-Myers Squibb Business Overview Table 162. Bristol-Myers Squibb Revenue in Immuno-oncology Drugs Business (2021-2026) & (US$ Million) Table 163. Bristol-Myers Squibb Immuno-oncology Drugs Product Portfolio Table 164. Bristol-Myers Squibb Recent Developments Table 165. Bio-Rad Laboratories, Inc. Company Information Table 166. Bio-Rad Laboratories, Inc. Business Overview Table 167. Bio-Rad Laboratories, Inc. Revenue in Immuno-oncology Drugs Business (2021-2026) & (US$ Million) Table 168. Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Product Portfolio Table 169. Bio-Rad Laboratories, Inc. Recent Developments Table 170. Bavarian Nordic Company Information Table 171. Bavarian Nordic Business Overview Table 172. Bavarian Nordic Revenue in Immuno-oncology Drugs Business (2021-2026) & (US$ Million) Table 173. Bavarian Nordic Immuno-oncology Drugs Product Portfolio Table 174. Bavarian Nordic Recent Developments Table 175. Avantor, Inc. Company Information Table 176. Avantor, Inc. Business Overview Table 177. Avantor, Inc. Revenue in Immuno-oncology Drugs Business (2021-2026) & (US$ Million) Table 178. Avantor, Inc. Immuno-oncology Drugs Product Portfolio Table 179. Avantor, Inc. Recent Developments Table 180. Agilent Technologies Inc. Company Information Table 181. Agilent Technologies Inc. Business Overview Table 182. Agilent Technologies Inc. Revenue in Immuno-oncology Drugs Business (2021-2026) & (US$ Million) Table 183. Agilent Technologies Inc. Immuno-oncology Drugs Product Portfolio Table 184. Agilent Technologies Inc. Recent Developments Table 185. Agenus Inc. Company Information Table 186. Agenus Inc. Business Overview Table 187. Agenus Inc. Revenue in Immuno-oncology Drugs Business (2021-2026) & (US$ Million) Table 188. Agenus Inc. Immuno-oncology Drugs Product Portfolio Table 189. Agenus Inc. Recent Developments Table 190. Aduro BioTech Company Information Table 191. Aduro BioTech Business Overview Table 192. Aduro BioTech Revenue in Immuno-oncology Drugs Business (2021-2026) & (US$ Million) Table 193. Aduro BioTech Immuno-oncology Drugs Product Portfolio Table 194. Aduro BioTech Recent Developments Table 195. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Immuno-oncology Drugs Product Image Figure 5. Global Immuno-oncology Drugs Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 6. Global Immuno-oncology Drugs Market Share by Type: 2025 VS 2032 Figure 7. Oncolytic Virus Product Figure 8. Immune System Modulators Product Figure 9. Immune Checkpoint Inhibitors Product Figure 10. Cancer Vaccines Product Figure 11. Others Product Figure 12. Global Immuno-oncology Drugs Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Immuno-oncology Drugs Market Share by Application: 2025 VS 2032 Figure 14. Clinics Product Figure 15. Hospitals Product Figure 16. Community Centers Product Figure 17. Global Immuno-oncology Drugs Market Size (US$ Million), Year-over-Year: 2021-2032 Figure 18. Global Immuno-oncology Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 19. Global Immuno-oncology Drugs Market Share by Region: 2025 VS 2032 Figure 20. Global Immuno-oncology Drugs Market Share by Players in 2025 Figure 21. Global Immuno-oncology Drugs Manufacturers Established Date Figure 22. Global Top 5 and 10 Immuno-oncology Drugs Players Market Share by Revenue in 2025 Figure 23. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 24. North America Immuno-oncology Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Immuno-oncology Drugs Market Share by Country (2021-2032) Figure 26. United States Immuno-oncology Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Canada Immuno-oncology Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 28. Mexico Immuno-oncology Drugs Market Share by Country (2021-2032) Figure 29. Europe Immuno-oncology Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Immuno-oncology Drugs Market Share by Country (2021-2032) Figure 31. Germany Immuno-oncology Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 32. France Immuno-oncology Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. U.K. Immuno-oncology Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 34. Italy Immuno-oncology Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Spain Immuno-oncology Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 36. Russia Immuno-oncology Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Netherlands Immuno-oncology Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 38. Nordic Countries Immuno-oncology Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Immuno-oncology Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Immuno-oncology Drugs Market Share by Country (2021-2032) Figure 41. China Immuno-oncology Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 42. Japan Immuno-oncology Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 43. South Korea Immuno-oncology Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 44. India Immuno-oncology Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 45. India Immuno-oncology Drugs Market Share by Country (2021-2032) Figure 46. Australia Immuno-oncology Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 47. China Taiwan Immuno-oncology Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 48. Southeast Asia Immuno-oncology Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 49. South America Immuno-oncology Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 50. South America Immuno-oncology Drugs Market Share by Country (2021-2032) Figure 51. Brazil Immuno-oncology Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 52. Argentina Immuno-oncology Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 53. Chile Immuno-oncology Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 54. Colombia Immuno-oncology Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 55. Peru Immuno-oncology Drugs Market Size YoY Growth (2021-2032) & (US$ Million) Figure 56. Sanofi S.A. Revenue Growth Rate in Immuno-oncology Drugs Business (2021-2026) Figure 57. Johnson & Johnson Revenue Growth Rate in Immuno-oncology Drugs Business (2021-2026) Figure 58. Merck & Co. Revenue Growth Rate in Immuno-oncology Drugs Business (2021-2026) Figure 59. Lonza Group Revenue Growth Rate in Immuno-oncology Drugs Business (2021-2026) Figure 60. Eli Lilly and Company Revenue Growth Rate in Immuno-oncology Drugs Business (2021-2026) Figure 61. Pfizer Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2021-2026) Figure 62. Ferring Pharmaceuticals Revenue Growth Rate in Immuno-oncology Drugs Business (2021-2026) Figure 63. Amgen, Inc Revenue Growth Rate in Immuno-oncology Drugs Business (2021-2026) Figure 64. AbbVie, Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2021-2026) Figure 65. AstraZeneca, Plc Revenue Growth Rate in Immuno-oncology Drugs Business (2021-2026) Figure 66. Spring Bank Pharmaceuticals, Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2021-2026) Figure 67. Prometheus Therapeutics & Diagnostics Revenue Growth Rate in Immuno-oncology Drugs Business (2021-2026) Figure 68. Novartis International AG Revenue Growth Rate in Immuno-oncology Drugs Business (2021-2026) Figure 69. Incyte Revenue Growth Rate in Immuno-oncology Drugs Business (2021-2026) Figure 70. ImmunoCellular Therapeutics Revenue Growth Rate in Immuno-oncology Drugs Business (2021-2026) Figure 71. Hoffmann-La Roche AG Revenue Growth Rate in Immuno-oncology Drugs Business (2021-2026) Figure 72. Gilead Sciences Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2021-2026) Figure 73. Galena Biopharma Revenue Growth Rate in Immuno-oncology Drugs Business (2021-2026) Figure 74. Enzo Biochem, Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2021-2026) Figure 75. EMD Serono, Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2021-2026) Figure 76. Dendreon Corporation Revenue Growth Rate in Immuno-oncology Drugs Business (2021-2026) Figure 77. Celldex Therapeutics Revenue Growth Rate in Immuno-oncology Drugs Business (2021-2026) Figure 78. Celgene Corporation Revenue Growth Rate in Immuno-oncology Drugs Business (2021-2026) Figure 79. Bristol-Myers Squibb Revenue Growth Rate in Immuno-oncology Drugs Business (2021-2026) Figure 80. Bio-Rad Laboratories, Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2021-2026) Figure 81. Bavarian Nordic Revenue Growth Rate in Immuno-oncology Drugs Business (2021-2026) Figure 82. Avantor, Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2021-2026) Figure 83. Agilent Technologies Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2021-2026) Figure 84. Agenus Inc. Revenue Growth Rate in Immuno-oncology Drugs Business (2021-2026) Figure 85. Aduro BioTech Revenue Growth Rate in Immuno-oncology Drugs Business (2021-2026)

Scope & coverage.

Types
  • Oncolytic Virus
  • Immune System Modulators
  • Immune Checkpoint Inhibitors
  • Cancer Vaccines
  • Others
Applications
  • Clinics
  • Hospitals
  • Community Centers
Companies covered
  • Sanofi S.A.
  • Johnson & Johnson
  • Merck & Co.
  • Lonza Group
  • Eli Lilly and Company
  • Pfizer Inc.
  • Ferring Pharmaceuticals
  • Amgen, Inc
  • AbbVie, Inc.
  • AstraZeneca, Plc
  • Spring Bank Pharmaceuticals, Inc.
  • Prometheus Therapeutics & Diagnostics
  • Novartis International AG
  • Incyte
  • ImmunoCellular Therapeutics
  • Hoffmann-La Roche AG
  • Gilead Sciences Inc.
  • Galena Biopharma
  • Enzo Biochem, Inc.
  • EMD Serono, Inc.
  • Dendreon Corporation
  • Celldex Therapeutics
  • Celgene Corporation
  • Bristol-Myers Squibb
  • Bio-Rad Laboratories, Inc.
  • Bavarian Nordic
  • Avantor, Inc.
  • Agilent Technologies Inc.
  • Agenus Inc.
  • Aduro BioTech

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Immuno-oncology Drugs by Type
  3. 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
  4. 2.2.2 Oncolytic Virus
  5. 2.2.3 Immune System Modulators
  6. 2.2.4 Immune Checkpoint Inhibitors
  7. 2.2.5 Cancer Vaccines
  8. 2.2.6 Others
  9. 2.3 Immuno-oncology Drugs by Application
  10. 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  11. 2.3.2 Clinics
  12. 2.3.3 Hospitals
  13. 2.3.4 Community Centers
  14. 2.4 Assumptions and Limitations
3 Immuno-oncology Drugs Breakdown Data by Type
  1. 3.1 Global Immuno-oncology Drugs Historic Market Size by Type (2021-2026)
  2. 3.2 Global Immuno-oncology Drugs Forecasted Market Size by Type (2027-2032)
4 Immuno-oncology Drugs Breakdown Data by Application
  1. 4.1 Global Immuno-oncology Drugs Historic Market Size by Application (2021-2026)
  2. 4.2 Global Immuno-oncology Drugs Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
  1. 5.1 Global Immuno-oncology Drugs Market Perspective (2021-2032)
  2. 5.2 Global Immuno-oncology Drugs Growth Trends by Region
  3. 5.2.1 Global Immuno-oncology Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 5.2.2 Immuno-oncology Drugs Historic Market Size by Region (2021-2026)
  5. 5.2.3 Immuno-oncology Drugs Forecasted Market Size by Region (2027-2032)
  6. 5.3 Immuno-oncology Drugs Market Dynamics
  7. 5.3.1 Immuno-oncology Drugs Industry Trends
  8. 5.3.2 Immuno-oncology Drugs Market Drivers
  9. 5.3.3 Immuno-oncology Drugs Market Challenges
  10. 5.3.4 Immuno-oncology Drugs Market Restraints
6 Market Competitive Landscape by Players
  1. 6.1 Global Top Immuno-oncology Drugs Players by Revenue
  2. 6.1.1 Global Top Immuno-oncology Drugs Players by Revenue (2021-2026)
  3. 6.1.2 Global Immuno-oncology Drugs Revenue Market Share by Players (2021-2026)
  4. 6.2 Global Immuno-oncology Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
  5. 6.3 Global Key Players of Immuno-oncology Drugs Head Office and Area Served
  6. 6.4 Global Immuno-oncology Drugs Players, Product Type & Application
  7. 6.5 Global Immuno-oncology Drugs Manufacturers Established Date
  8. 6.6 Global Immuno-oncology Drugs Market CR5 and HHI
  9. 6.7 Global Players Mergers & Acquisition
7 North America
  1. 7.1 North America Immuno-oncology Drugs Market Size (2021-2032)
  2. 7.2 North America Immuno-oncology Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 7.3 North America Immuno-oncology Drugs Market Size by Country (2021-2026)
  4. 7.4 North America Immuno-oncology Drugs Market Size by Country (2027-2032)
  5. 7.5 United States
  6. 7.5 United States
  7. 7.6 Canada
  8. 7.7 Mexico
8 Europe
  1. 8.1 Europe Immuno-oncology Drugs Market Size (2021-2032)
  2. 8.2 Europe Immuno-oncology Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 8.3 Europe Immuno-oncology Drugs Market Size by Country (2021-2026)
  4. 8.4 Europe Immuno-oncology Drugs Market Size by Country (2027-2032)
  5. 8.5 Germany
  6. 8.6 France
  7. 8.7 U.K.
  8. 8.8 Italy
  9. 8.9 Spain
  10. 8.10 Russia
  11. 8.11 Netherlands
  12. 8.12 Nordic Countries
9 Asia-Pacific
  1. 9.1 Asia-Pacific Immuno-oncology Drugs Market Size (2021-2032)
  2. 9.2 Asia-Pacific Immuno-oncology Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 9.3 Asia-Pacific Immuno-oncology Drugs Market Size by Country (2021-2026)
  4. 9.4 Asia-Pacific Immuno-oncology Drugs Market Size by Country (2027-2032)
  5. 9.5 China
  6. 9.6 Japan
  7. 9.7 South Korea
  8. 9.8 India
  9. 9.9 Australia
  10. 9.10 China Taiwan
  11. 9.11 Southeast Asia
10 South America
  1. 10.1 South America Immuno-oncology Drugs Market Size (2021-2032)
  2. 10.2 South America Immuno-oncology Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 10.3 South America Immuno-oncology Drugs Market Size by Country (2021-2026)
  4. 10.4 South America Immuno-oncology Drugs Market Size by Country (2027-2032)
  5. 10.5 Brazil
  6. 10.6 Argentina
  7. 10.7 Chile
  8. 10.8 Colombia
  9. 10.9 Peru
11 Middle East & Africa
  1. 11.1 Middle East & Africa Immuno-oncology Drugs Market Size (2021-2032)
  2. 11.2 Middle East & Africa Immuno-oncology Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 11.3 Middle East & Africa Immuno-oncology Drugs Market Size by Country (2021-2026)
  4. 11.4 Middle East & Africa Immuno-oncology Drugs Market Size by Country (2027-2032)
  5. 11.5 Saudi Arabia
  6. 11.6 Israel
  7. 11.7 United Arab Emirates
  8. 11.8 Turkey
  9. 11.9 Iran
  10. 11.10 Egypt
12 Players Profiled
  1. 12.1 Sanofi S.A.
  2. 12.1.1 Sanofi S.A. Company Information
  3. 12.1.2 Sanofi S.A. Business Overview
  4. 12.1.3 Sanofi S.A. Revenue in Immuno-oncology Drugs Business (2021-2026)
  5. 12.1.4 Sanofi S.A. Immuno-oncology Drugs Product Portfolio
  6. 12.1.5 Sanofi S.A. Recent Developments
  7. 12.2 Johnson & Johnson
  8. 12.2.1 Johnson & Johnson Company Information
  9. 12.2.2 Johnson & Johnson Business Overview
  10. 12.2.3 Johnson & Johnson Revenue in Immuno-oncology Drugs Business (2021-2026)
  11. 12.2.4 Johnson & Johnson Immuno-oncology Drugs Product Portfolio
  12. 12.2.5 Johnson & Johnson Recent Developments
  13. 12.3 Merck & Co.
  14. 12.3.1 Merck & Co. Company Information
  15. 12.3.2 Merck & Co. Business Overview
  16. 12.3.3 Merck & Co. Revenue in Immuno-oncology Drugs Business (2021-2026)
  17. 12.3.4 Merck & Co. Immuno-oncology Drugs Product Portfolio
  18. 12.3.5 Merck & Co. Recent Developments
  19. 12.4 Lonza Group
  20. 12.4.1 Lonza Group Company Information
  21. 12.4.2 Lonza Group Business Overview
  22. 12.4.3 Lonza Group Revenue in Immuno-oncology Drugs Business (2021-2026)
  23. 12.4.4 Lonza Group Immuno-oncology Drugs Product Portfolio
  24. 12.4.5 Lonza Group Recent Developments
  25. 12.5 Eli Lilly and Company
  26. 12.5.1 Eli Lilly and Company Company Information
  27. 12.5.2 Eli Lilly and Company Business Overview
  28. 12.5.3 Eli Lilly and Company Revenue in Immuno-oncology Drugs Business (2021-2026)
  29. 12.5.4 Eli Lilly and Company Immuno-oncology Drugs Product Portfolio
  30. 12.5.5 Eli Lilly and Company Recent Developments
  31. 12.6 Pfizer Inc.
  32. 12.6.1 Pfizer Inc. Company Information
  33. 12.6.2 Pfizer Inc. Business Overview
  34. 12.6.3 Pfizer Inc. Revenue in Immuno-oncology Drugs Business (2021-2026)
  35. 12.6.4 Pfizer Inc. Immuno-oncology Drugs Product Portfolio
  36. 12.6.5 Pfizer Inc. Recent Developments
  37. 12.7 Ferring Pharmaceuticals
  38. 12.7.1 Ferring Pharmaceuticals Company Information
  39. 12.7.2 Ferring Pharmaceuticals Business Overview
  40. 12.7.3 Ferring Pharmaceuticals Revenue in Immuno-oncology Drugs Business (2021-2026)
  41. 12.7.4 Ferring Pharmaceuticals Immuno-oncology Drugs Product Portfolio
  42. 12.7.5 Ferring Pharmaceuticals Recent Developments
  43. 12.8 Amgen, Inc
  44. 12.8.1 Amgen, Inc Company Information
  45. 12.8.2 Amgen, Inc Business Overview
  46. 12.8.3 Amgen, Inc Revenue in Immuno-oncology Drugs Business (2021-2026)
  47. 12.8.4 Amgen, Inc Immuno-oncology Drugs Product Portfolio
  48. 12.8.5 Amgen, Inc Recent Developments
  49. 12.9 AbbVie, Inc.
  50. 12.9.1 AbbVie, Inc. Company Information
  51. 12.9.2 AbbVie, Inc. Business Overview
  52. 12.9.3 AbbVie, Inc. Revenue in Immuno-oncology Drugs Business (2021-2026)
  53. 12.9.4 AbbVie, Inc. Immuno-oncology Drugs Product Portfolio
  54. 12.9.5 AbbVie, Inc. Recent Developments
  55. 12.10 AstraZeneca, Plc
  56. 12.10.1 AstraZeneca, Plc Company Information
  57. 12.10.2 AstraZeneca, Plc Business Overview
  58. 12.10.3 AstraZeneca, Plc Revenue in Immuno-oncology Drugs Business (2021-2026)
  59. 12.10.4 AstraZeneca, Plc Immuno-oncology Drugs Product Portfolio
  60. 12.10.5 AstraZeneca, Plc Recent Developments
  61. 12.11 Spring Bank Pharmaceuticals, Inc.
  62. 12.11.1 Spring Bank Pharmaceuticals, Inc. Company Information
  63. 12.11.2 Spring Bank Pharmaceuticals, Inc. Business Overview
  64. 12.11.3 Spring Bank Pharmaceuticals, Inc. Revenue in Immuno-oncology Drugs Business (2021-2026)
  65. 12.11.4 Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Product Portfolio
  66. 12.11.5 Spring Bank Pharmaceuticals, Inc. Recent Developments
  67. 12.12 Prometheus Therapeutics & Diagnostics
  68. 12.12.1 Prometheus Therapeutics & Diagnostics Company Information
  69. 12.12.2 Prometheus Therapeutics & Diagnostics Business Overview
  70. 12.12.3 Prometheus Therapeutics & Diagnostics Revenue in Immuno-oncology Drugs Business (2021-2026)
  71. 12.12.4 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Product Portfolio
  72. 12.12.5 Prometheus Therapeutics & Diagnostics Recent Developments
  73. 12.13 Novartis International AG
  74. 12.13.1 Novartis International AG Company Information
  75. 12.13.2 Novartis International AG Business Overview
  76. 12.13.3 Novartis International AG Revenue in Immuno-oncology Drugs Business (2021-2026)
  77. 12.13.4 Novartis International AG Immuno-oncology Drugs Product Portfolio
  78. 12.13.5 Novartis International AG Recent Developments
  79. 12.14 Incyte
  80. 12.14.1 Incyte Company Information
  81. 12.14.2 Incyte Business Overview
  82. 12.14.3 Incyte Revenue in Immuno-oncology Drugs Business (2021-2026)
  83. 12.14.4 Incyte Immuno-oncology Drugs Product Portfolio
  84. 12.14.5 Incyte Recent Developments
  85. 12.15 ImmunoCellular Therapeutics
  86. 12.15.1 ImmunoCellular Therapeutics Company Information
  87. 12.15.2 ImmunoCellular Therapeutics Business Overview
  88. 12.15.3 ImmunoCellular Therapeutics Revenue in Immuno-oncology Drugs Business (2021-2026)
  89. 12.15.4 ImmunoCellular Therapeutics Immuno-oncology Drugs Product Portfolio
  90. 12.15.5 ImmunoCellular Therapeutics Recent Developments
  91. 12.16 Hoffmann-La Roche AG
  92. 12.16.1 Hoffmann-La Roche AG Company Information
  93. 12.16.2 Hoffmann-La Roche AG Business Overview
  94. 12.16.3 Hoffmann-La Roche AG Revenue in Immuno-oncology Drugs Business (2021-2026)
  95. 12.16.4 Hoffmann-La Roche AG Immuno-oncology Drugs Product Portfolio
  96. 12.16.5 Hoffmann-La Roche AG Recent Developments
  97. 12.17 Gilead Sciences Inc.
  98. 12.17.1 Gilead Sciences Inc. Company Information
  99. 12.17.2 Gilead Sciences Inc. Business Overview
  100. 12.17.3 Gilead Sciences Inc. Revenue in Immuno-oncology Drugs Business (2021-2026)
  101. 12.17.4 Gilead Sciences Inc. Immuno-oncology Drugs Product Portfolio
  102. 12.17.5 Gilead Sciences Inc. Recent Developments
  103. 12.18 Galena Biopharma
  104. 12.18.1 Galena Biopharma Company Information
  105. 12.18.2 Galena Biopharma Business Overview
  106. 12.18.3 Galena Biopharma Revenue in Immuno-oncology Drugs Business (2021-2026)
  107. 12.18.4 Galena Biopharma Immuno-oncology Drugs Product Portfolio
  108. 12.18.5 Galena Biopharma Recent Developments
  109. 12.19 Enzo Biochem, Inc.
  110. 12.19.1 Enzo Biochem, Inc. Company Information
  111. 12.19.2 Enzo Biochem, Inc. Business Overview
  112. 12.19.3 Enzo Biochem, Inc. Revenue in Immuno-oncology Drugs Business (2021-2026)
  113. 12.19.4 Enzo Biochem, Inc. Immuno-oncology Drugs Product Portfolio
  114. 12.19.5 Enzo Biochem, Inc. Recent Developments
  115. 12.20 EMD Serono, Inc.
  116. 12.20.1 EMD Serono, Inc. Company Information
  117. 12.20.2 EMD Serono, Inc. Business Overview
  118. 12.20.3 EMD Serono, Inc. Revenue in Immuno-oncology Drugs Business (2021-2026)
  119. 12.20.4 EMD Serono, Inc. Immuno-oncology Drugs Product Portfolio
  120. 12.20.5 EMD Serono, Inc. Recent Developments
  121. 12.21 Dendreon Corporation
  122. 12.21.1 Dendreon Corporation Company Information
  123. 12.21.2 Dendreon Corporation Business Overview
  124. 12.21.3 Dendreon Corporation Revenue in Immuno-oncology Drugs Business (2021-2026)
  125. 12.21.4 Dendreon Corporation Immuno-oncology Drugs Product Portfolio
  126. 12.21.5 Dendreon Corporation Recent Developments
  127. 12.22 Celldex Therapeutics
  128. 12.22.1 Celldex Therapeutics Company Information
  129. 12.22.2 Celldex Therapeutics Business Overview
  130. 12.22.3 Celldex Therapeutics Revenue in Immuno-oncology Drugs Business (2021-2026)
  131. 12.22.4 Celldex Therapeutics Immuno-oncology Drugs Product Portfolio
  132. 12.22.5 Celldex Therapeutics Recent Developments
  133. 12.23 Celgene Corporation
  134. 12.23.1 Celgene Corporation Company Information
  135. 12.23.2 Celgene Corporation Business Overview
  136. 12.23.3 Celgene Corporation Revenue in Immuno-oncology Drugs Business (2021-2026)
  137. 12.23.4 Celgene Corporation Immuno-oncology Drugs Product Portfolio
  138. 12.23.5 Celgene Corporation Recent Developments
  139. 12.24 Bristol-Myers Squibb
  140. 12.24.1 Bristol-Myers Squibb Company Information
  141. 12.24.2 Bristol-Myers Squibb Business Overview
  142. 12.24.3 Bristol-Myers Squibb Revenue in Immuno-oncology Drugs Business (2021-2026)
  143. 12.24.4 Bristol-Myers Squibb Immuno-oncology Drugs Product Portfolio
  144. 12.24.5 Bristol-Myers Squibb Recent Developments
  145. 12.25 Bio-Rad Laboratories, Inc.
  146. 12.25.1 Bio-Rad Laboratories, Inc. Company Information
  147. 12.25.2 Bio-Rad Laboratories, Inc. Business Overview
  148. 12.25.3 Bio-Rad Laboratories, Inc. Revenue in Immuno-oncology Drugs Business (2021-2026)
  149. 12.25.4 Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Product Portfolio
  150. 12.25.5 Bio-Rad Laboratories, Inc. Recent Developments
  151. 12.26 Bavarian Nordic
  152. 12.26.1 Bavarian Nordic Company Information
  153. 12.26.2 Bavarian Nordic Business Overview
  154. 12.26.3 Bavarian Nordic Revenue in Immuno-oncology Drugs Business (2021-2026)
  155. 12.26.4 Bavarian Nordic Immuno-oncology Drugs Product Portfolio
  156. 12.26.5 Bavarian Nordic Recent Developments
  157. 12.27 Avantor, Inc.
  158. 12.27.1 Avantor, Inc. Company Information
  159. 12.27.2 Avantor, Inc. Business Overview
  160. 12.27.3 Avantor, Inc. Revenue in Immuno-oncology Drugs Business (2021-2026)
  161. 12.27.4 Avantor, Inc. Immuno-oncology Drugs Product Portfolio
  162. 12.27.5 Avantor, Inc. Recent Developments
  163. 12.28 Agilent Technologies Inc.
  164. 12.28.1 Agilent Technologies Inc. Company Information
  165. 12.28.2 Agilent Technologies Inc. Business Overview
  166. 12.28.3 Agilent Technologies Inc. Revenue in Immuno-oncology Drugs Business (2021-2026)
  167. 12.28.4 Agilent Technologies Inc. Immuno-oncology Drugs Product Portfolio
  168. 12.28.5 Agilent Technologies Inc. Recent Developments
  169. 12.29 Agenus Inc.
  170. 12.29.1 Agenus Inc. Company Information
  171. 12.29.2 Agenus Inc. Business Overview
  172. 12.29.3 Agenus Inc. Revenue in Immuno-oncology Drugs Business (2021-2026)
  173. 12.29.4 Agenus Inc. Immuno-oncology Drugs Product Portfolio
  174. 12.29.5 Agenus Inc. Recent Developments
  175. 12.30 Aduro BioTech
  176. 12.30.1 Aduro BioTech Company Information
  177. 12.30.2 Aduro BioTech Business Overview
  178. 12.30.3 Aduro BioTech Revenue in Immuno-oncology Drugs Business (2021-2026)
  179. 12.30.4 Aduro BioTech Immuno-oncology Drugs Product Portfolio
  180. 12.30.5 Aduro BioTech Recent Developments
13 Report Conclusion
    14 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst